Lupus Anticoagulants and Thrombosis: Clinical Association of Different Coagulation and Immunologic Tests

Summary

The dilute Russell’s viper venom time (dRVVT) and the kaolin clotting time (KCT) are two among the most commonly used coagulation tests for the detection of lupus anticoagulants. The dRVVT seems superior to the KCT in identifying LA-positive patients at risk of thrombosis. However, this relationship is greatly influenced by both the source of reagents and the instrumentation employed to carry out the assays. Therefore, 4 dRVVTs (“home-made” dRVVT, DVV test, Bioclot LA, LA Screen), and one KCT (Kaoclot) were performed in two centers and compared for their retrospective correlation with the thrombotic complications of 72 patients with a previously established diagnosis of lupus anticoagulants. Two other assays (“home-made” KCT, and Colloidal Silica Clotting Time, CSCT) were performed in one of the two centers, and compared with Kaoclot for their clinical correlations in the same population of patients, 44 of whom (61%) had suffered from arterial and/or venous thrombosis. A rather good degree of inter-laboratory and inter-assay correlations of the different tests was found. However, a statistically significant association with thrombosis was found only with the coagulation profile generated using the “homemade” dRVVT. When the commercially available dRVVTs were used, none of the coagulation profiles remained associated with thrombosis. When the assays were analyzed separately, the association with thrombosis was statistically significant for LA screen (p = 0.0019), DVV test (p = 0.0043), and Bioclot (p = 0.0255), and of borderline significance for the “home-made” dRVVT (p = 0.0503) in one center. This last assay was also significantly associated with thrombosis in the other center (p = 0.0139). When venous and arterial thrombosis were considered separately, DVV test was statistically associated with venous thrombosis in both centers (p = 0.0076 and p = 0.0187, respectively), and LA screen in one center (p = 0.0303). No dRVVT was found to correlate with arterial thrombosis. Kaoclot, Colloidal Silica Clotting Time, and the “home-made” KCT did not correlate with thrombosis. The prevalence of IgG and/or IgM antibodies to cardiolipin, β2-glycoprotein I and prothrombin were 74%, 86% and 85%, respectively. Increased titers of IgG anticardiolipin antibodies were associated with arterial thrombosis (p = 0.0375), whereas IgM anti-β2-glycoprotein I antibodies were associated with venous thrombosis (p = 0.0433). In conclusion, these retrospective data support the notion that the dRVVT, rather than other coagulation or ELISA tests, are able to identify lupus anticoagulant-positive patients at risk of thrombosis. This property appears common to several commercially available dRVVT kits, making this type of assay the ideal target of future efforts of laboratory standardization.

Keywords

Lupus anticoagulants - thrombosis - dRVVT - antiphospholipid antibodies

• References

• 1 Triplett DA. Lupus anticoagulants/antiphospholipid-protein antibodies: the great imposters. Lupus 1996; 05: 431-5.
• 2 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG’s (LA) are not directed to phospholipid only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-32.
• 3 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipidbinding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci (USA) 1990; 87: 4120-4.
• 4 Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda PJCVriesman, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7.
• 5 Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell’s viper venom time distinguish between prothrombin and β2glycoprotein I-dependent antiphospholipid antibodies. Blood 1995; 86: 617-23.
• 6 Galli M, Finazzi G, Norbis F, Marziali S, Marchioli R, Barbui T. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Thromb Haemost 1999; 81: 695-700.
• 7 Simmelink MJA, Horbach DA, vOort E, Derksen RHWM, deGroot P. dRVVT is a much better predictor than KCT for the risk of thrombosis. Lupus 1998; 07: 219 (Suppl. 02) (abstract B65).
• 8 Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, Stevens P, Hirsh J. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-91.
• 9 Horbach DA, vOort E, Donders RCJM, Derksen RHWM, deGroot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 916-24.
• 10 Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 1185-90.
• 11 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell’s viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869-874.
• 12 Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978; 40: 143-51.
• 13 Norbis F, Barbui T, Galli M. Dilute Russell’s viper venom time and colloidal silica clotting time for the identification of the phospholipid-dependent inhibitors of coagulation. Thromb Res 1997; 85: 427-31.
• 14 Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by enzyme-linked immunosorbent assay: standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738-44.
• 15 Harris EN, Gharavi AE, Hughes GRV. The anticardiolipin assay. In: Harris EN, Exner T, Hughes GRV, Asherson RA. (eds). Phospholipid-binding antibodies. Boca Raton: CRC Press; 1991: 175-87.
• 16 Arvieux J, Roussel B, Jacob MC, Colomb MG. Measurement of antiphospholipid antibodies by ELISA using β2-glycoprotein I as an antigen. J Immunol Meth 1991; 143: 223-9.
• 17 Galli M, Beretta G, Daldossi M, Bevers E, Barbui T. Different anticoagulant properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1997; 77: 486-91.
• 18 Galli M, Finazzi G, Barbui T. Antiphospholipid antibodies: predictive value of laboratory tests. Thromb Haemost 1997; 78: 75-8.
• 19 Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992; 68: 297-300.
• 20 Barbui T, Finazzi G. Clinical trials on antiphospholipid syndrome: what is done and what is needed?. Lupus 1994; 03: 303-8.
• 21 Foster WM, Triplett DA, Barna LK. Evaluation of 7 dilute Russell’s viper venom time (dRVVT) kits. Lupus 1994; 03: 351 (abstract 155).
• 22 Norbis F, Barbui T, Galli M. Comparison of two Russell’s viper venom time (dRVVT) for distinguishing the phospholipid-dependent inhibitors of coagulation. Thromb Haemost. 1997 (suppl.) 331. (abstr 1356).
• 23 Callahan JB, Manares CC, Moll S, Ortel TL. Inability to distinguish between thrombotic and non-thrombotic antiphospholipid antibody positive patients with kaolin clotting time and dilute Russell’s viper venom assay ratio. Lupus 1996; 05: 530 (abstract 111).
• 24 Galli M, Ruggeri L, Barbui T. Differential effects of anti-β2-glycoprotein I and anti-prothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998; 91: 1999-2004.
• 25 Lawrie AS, Mackie J, Purdy S, Machin SJ. The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers. Thromb Haemost 1999; 81: 758-62.